HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Cosmetics Manufacturing Survey Under Way; J&J, Colgate Jointly Defending Talc In California; News In Brief

Executive Summary

FDA moves ahead with its plan to survey the cosmetics industry on current manufacturing practices, with 900 companies selected for invitations to participate. More cosmetics news in brief.

You may also be interested in...



FDA Proposes Priorities For Cosmetic Ingredient Review: Mica, Probiotics, CBD

Nakissa Sadrieh, director of cosmetics at FDA and the agency’s CIR liaison, floated the three potential review priorities at the CIR Expert Panel’s April 8-9 meeting in Washington. It’s the most for-cause targets proposed by the agency in recent memory, and CIR leadership noted that they pose considerable challenges.

FDA Targets Spring 2019 For Cosmetics Manufacturing Survey; PCPC Input Taken

From the Personal Care Products Council’s standpoint, FDA’s planned survey of current manufacturing practices in the cosmetics sector isn’t necessary, but the group provided input to contractor RTI to help develop the instrument for optimal utility. Pending OMB approval, FDA aims to launch the survey in spring 2019.

Cosmetic Talc Under Scrutiny As Liability Buzzards Circle

Plaintiff’s attorneys are tracking reports of asbestos-contaminated cosmetics at specialty retail stores, signaling a possible new wave of talc-related litigation to come. The issue also has the attention of NGOs, legislators and FDA.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148759

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel